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Summary The proton pump inhibitor, lansoprazole, is reported to have acid secretion inhibiting
effect as well as anti-inflammatory effects such as inhibition of cytokine secretion from
inflammatory cells. Clinically, excellent efficacy of lansoprazole is reported for not only gastric
ulcer but also gastroesophageal reflux disease (GERD). Since GERD is categorized endo-
scopically into erosive esophagitis and non-erosive reflux disease, it is important to make
accurate assessment of any improvement in the inflammatory process when using endoscopic
ultrasonography (EUS) capable of visualizing the submucosal structure. We report here our
experience in assessing the effect of treatment with lansoprazole on esophageal wall structure
using EUS in patients with GERD. At baseline (before treatment), EUS showed abnormalities
in the mucosa, submucosa and muscularis propria caused by inflammation, thickening of the
entire esophageal wall and changes in the contractile properties of esophageal smooth muscles
reflecting the effects of inflammation on the entire wall of the lower esophagus in reflux
esophagitis regardless of whether it is erosive or endoscopically-negative. Treatment with
lansoprazole resulted in normalization of esophageal wall structure and improvement of
motility, suggesting that lansoprazole improves not only mucosal inflammation but also
submucosal inflammation in GERD.
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Lansoprazole and Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) is a chronic
disorder that can potentially have a negative impact on
quality of life (QOL) and increase the risk of esophageal
damage [1–3]. While a large proportion of individuals report
occasional or monthly heartburn, approximately 20% of the
US adult population experience reflux symptoms on a
weekly basis [4].
GERD is currently subclassified based on endoscopic
findings into erosive esophagitis (EE) and non-erosive
reflux disease (NERD) [5]. Although patients with EE have
acid reflux, those with endoscopically-negative reflux disease
represent a heterogeneous group for whom acid reflux is an
explanation in some but not all. Previous studies indicated
that about 50% of patients with endoscopically-negative
disease have no evidence of pathological acid reflux as
confirmed by pH monitoring and therefore, do not have
NERD [6, 7]. The Rome III Committee has suggested that
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such patients suffer from “functional heartburn” [8].
Proton pump inhibitor (PPI) therapy is effective for acid-
related symptoms. Lansoprazole, a substituted benzimidazole,
selectively inhibits H, K-ATPase in the parietal cell membrane,
and reduces gastric acid secretion [9]. Lansoprazole is more
effective in the management of duodenal ulcer, gastric ulcer,
and GERD and provides a faster relief of symptoms and
healing than H2-receptor antagonists (H2-RAs) [10–12].
However, to our knowledge, the effects of lansoprazole on
mucosal and entire wall injury of the lower esophagus have
not evaluated.
Histopathological Changes in Lower Esophagus in
Patients with GERD
Histopathological abnormalities have been described in
both EE and NERD. Studies of esophageal mucosa exposed
to luminal acidity by transmission electron microscopy (TEM)
indicated that dilation of intercellular spaces is a useful marker
of esophageal damage [13, 14]. Recently, magnifying endo-
scopy has also shown that the presence of inflammatory
cells, hyperplastic changes in the epithelium and dilated
vessels in the papillae are recognized as histopathological
markers of reflux disease, even in macroscopically-intact
esophageal mucosa [15]. These changes precede the onset of
macroscopic and histological lesions, and thus represent the
earliest pathological alterations present in both EE and
NERD. Furthermore, the presence of dilated intercellular
spaces in acid-exposed rabbit esophagus has been related to
episodes of high-acid content in the esophageal lumen,
which damage intercellular junctions, reduce transepithelial
resistance and increase paracellular permeability in the acid-
damaged esophageal epithelium [16]. Thus, acidification of
the intercellular space and of the cytosol seems to promote
cell edema and necrosis.
Endoscopic Ultrasonography Analysis of Esophageal
Wall
Endoscopy and examination of biopsy specimens are
important for the diagnosis of EE and NERD, but their
importance is limited to mucosal injury, such as erythema,
edema of the mucosa, erosions and ulcers. Endoscopic
ultrasonography (EUS) is the only technique that allows
detailed  in vivo analysis of the esophageal wall and
neighboring organs [17]. Therefore, EUS has been used
for evaluation of the width, depth of ulcer craters, staging
of cancers of the gastrointestinal (GI) tract, assessment of
submucosal tumors and gut neuroendocrine tumors [18, 19].
On EUS, the esophageal wall is seen to consist of five
layers of different echogenicities, roughly corresponding to
the anatomic layers. We and others have reported that the
thickness of the esophageal wall ranges between 2.43 mm
and 0.16 mm at the gastroesophageal junction in normal
subjects [20, 21]. In GERD, EUS can visualize changes in
the layer structure with localized or diffuse thickening
(Fig. 1) [21]. In our study, the total thicknesses of the lower
esophageal wall, submucosal layer and muscularis propria
layer measured by EUS in 20 normal adults (13 males and 7
females, age: 55 ± 20 years) were 2.44 ± 0.4, 1.03 ± 0.2, and
0.98 ± 0.2 mm (mean ± SD), respectively. The respective
mean total wall thickness and submucosal thickness were
significantly greater in 25 patients with EE and NERD (14
males and 11 females, age: 65 ± 13 years, Table 1) [21]. A
number of investigators have reported that such changes in
the esophageal wall are associated with not only irreversible
fibrosis [22], but also reversible edema and inflammatory
cell infiltration [23].
Fig. 1. Endoscopic ultrasonographic images of the esophageal
wall. Comparison of submucosal and muscular layers
between normal subjects (A) and patients with reflux
esophagitis (B). Note the marked thickening of the
submucosal and muscular layers in (B) with changes in
echo density. Reprinted with permission [21].
Table 1. EUS evaluation of esophageal wall and Los Angeles classification
control 
(n = 20)
Grade O 
(n = 4)
Grade A 
(n = 12)
Grade B 
(n = 5)
Grade C 
(n = 2)
Grade D 
(n = 2)
Total wall thickness (mm) 2.44 ± 0.4 3.67 ± 1.5a 3.65 ± 0.8a 4.38 ± 1.4a,b 3.10 ± 1.5 4.0 ± 1.4a
Submucosal layer (mm) 1.03 ± 0.2 1.36 ± 0.9 1.38 ± 0.3c 1.64 ± 0.5c 1.22 ± 0.5 1.46 ± 0.3
Muscularis propria layer (mm) 0.98 ± 0.2 1.27 ± 0.8 1.24 ± 0.3 1.36 ± 0.3 1.11 ± 0.4 1.13 ± 0.2
Data are mean ± SD (mm, a: p<0.001, vs control, b: p<0.05, vs Grade A, c: p<0.05, vs control)
Reprinted with permission [21].S. Mine et al.
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Sustained Esophageal Contractions
There is evidence to suggest that EUS-detectable increase
in esophageal wall thickness and abnormalities of wall
architecture correlate with inflammatory changes of esophageal
wall as well as mechanical changes in GERD. Sustained
esophageal contractions (SEC) are one of mechanisms
proposed to explain the pathogenesis of heartburn in NERD.
SEC, which represent prolonged contractions of the eso-
phageal longitudinal smooth muscles, can be detected in
vivo in humans as an increase in esophageal wall thickness
by high-frequency EUS [24]. The concept that SEC are
the cause of heartburn in NERD evolved from observations
in a dozen of patients with GERD [25]. For instance,
SEC were identified in all subjects during continuous
intraluminal ultrasonography and correlated with the
symptom of heartburn and acid reflux on pH monitoring
(Bernstein test) [26]. In addition, another group reported that
the positive correlation between SEC and heartburn in
GERD is paralleled by an equally strong correlation between
SEC and spontaneous chest pain in patients with atypical
chest complaints [27].
Taken together, these data suggest that SEC correlate with
chest pain of esophageal origin and impaired esophageal acid
clearance and that it may be one expression of inflammatory
damage of the muscle layer of the lower esophagus.
Lansoprazole Results in Improvement of Esophageal
Wall Thickness in Patients with GERD
While most studies of GERD include patients with EE
and NERD, support for the use of PPIs in patients with
milder forms of the disease comes from recently conducted
trials that documented the efficacy of PPIs as well as their
superiority to H2-RA [28–30]. However, EUS evaluation of
the healing process of GERD following treatment with PPI is
intriguing. We compared the effects of lansoprazole and H2-
RA in patients with GERD by using EUS before treatment
and after completion of treatment.
In our study, two observations concerning EUS assessment
deserve comment. First, lansoprazole administered at a dose
of 30 mg/day for 6 weeks resulted in rapid improvement of
submucosal thickness of the lower esophagus as well as
thickness of the entire wall of the lower esophagus. In
contrast, treatment with famotidine, a H2-RA, for 6 weeks
failed to improve these abnormalities (Table 2) [21]. Second,
the stratal structure of the esophageal wall and a good QOL
were well maintained in the lansoprazole-treatment group,
but reduction of the esophageal submucosal layer was
observed with no change in the mucosal surface in the
famotidine-treatment group (Fig. 2) [31].
The clinical improvement after PPI treatment in patients
with EE can be related to the endoscopically-confirmed
disappearance of EE; while in the case of NERD, where the
esophageal mucosa appears normal at endoscopy and
frequently also at histology, there was no improvement in any
parameter that can explain the improvement of symptoms
after treatment [32]. Recently, TEM demonstrated that PPI
might induce ultrastructural healing of mucosal damage in
both EE, NERD and asymptomatic subjects, based on
complete resolution of widening of intercellular spaces [33].
Likewise, the acid control and anti-inflammatory actions of
lansoprazole may have suppressive effects on the mucosal
surface as well as inflammatory cell infiltration into the
esophageal wall and may reverse alterations in the thickness
of esophageal wall and abnormal architecture.
Furthermore, EUS analysis showed that treatment with
lansoprazole improved esophageal wall structure, reduced
esophageal wall thickness and persistent SEC [21,  31].
These changes suggest that the effects of lansoprazole are
mediated through amelioration of esophageal motility and
improvement of inflammation in GERD. Several investigators
have reported that lansoprazole have potent inhibitory
effects on spontaneous contractions and cause dose-dependent
relaxation of smooth muscle in vitro [ 34,  35], probably
through blockade of calcium channels. Therefore, lansoprazole
Table 2. Change in esophageal wall layers after PPI and H2-RA treatment
Lansoprazole (30 mg)/famotidine (40 mg) pretreatment after 6 weeks after 12 weeks
Total wall thickness 4.28 ± 0.98a 2.70 ± 0.34b 3.34 ± 0.94a,c
Submucosal layer 1.65 ± 0.40a 1.16 ± 0.19b 1.44 ± 0.34
Muscularis propria layer 1.46 ± 0.41 1.05 ± 0.17 1.20 ± 0.24
Famotidine (40 mg)/lansoprazole (30 mg)
Total wall thickness 4.06 ± 0.74a 4.48 ± 1.11a,b 2.92 ± 0.73c
Submucosal layer 1.46 ± 0.48 1.75 ± 0.48 1.28 ± 0.30c
Muscularis propria layer 1.24 ± 0.25 1.55 ± 0.47 1.10 ± 0.20
Data are mean ± SD, (mm)
a: p<0.005 vs control, b: p<0.05 vs pretreatment, c: p<0.05 vs after 6weeks treatment
Reprinted with permission [21].Lansoprazole for Esophageal Submucosal Injury
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may also improve esophageal dysmotility through inhibitory
effects on contractions of esophageal smooth muscles.
In summary, using EUS, we reported the presence of
esophageal wall thickening and abnormal architecture in
ENRD as well as EE, and that lansoprazole was superior
to H2-RAs in reversing the changes in esophageal wall
thickness and abnormal architecture. This suggests that the
lansoprazole treatment can improve esophageal submucosal
injury as well as esophageal dysmotility.
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